Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
November 21, 2023 06:00 ET
|
Connect Biopharma Holdings Limited
Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens...
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
November 20, 2023 16:41 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage...
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
September 12, 2023 16:15 ET
|
Connect Biopharma Holdings Limited
Key data readouts with Company’s lead drug candidate rademikibart expected in the fourth quarter of 2023 Topline results from Stage 2 of the China pivotal trial in atopic dermatitisTopline results...
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
September 12, 2023 06:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma to Participate in Upcoming September Investor Conferences
August 24, 2023 18:21 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
July 10, 2023 08:00 ET
|
Connect Biopharma Holdings Limited
Four poster presentations provided detailed and new data on the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes, and improvements in patient reported...
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
July 05, 2023 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, July 05, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
June 01, 2023 16:05 ET
|
Connect Biopharma Holdings Limited
Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the induction...
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
April 11, 2023 16:05 ET
|
Connect Biopharma Holdings Limited
CDE’s Pre-NDA Feedback Confirms CBP-201 for Atopic Dermatitis on Track for NDA Submission in China by End of First Quarter 2024 SAN DIEGO and TAICANG, SUZHOU, China, April 11, 2023 (GLOBE NEWSWIRE)...
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
February 06, 2023 08:30 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven...